Jul 10, 2024
Twice before WaveData to have looked into this subject only to find there is no link between product value and the delay in the introduction of Category M. However, time moves on, so we thought we’d repeat the analysis, partly because of a recent client request, and...
Jun 18, 2024
Prompted by a Client’s questions about Category M and the formula that goes behind it to drive Pharmacy profitability, we asked Charles Joynson, WaveData MD, to have a closer look at Category M to see if he can make any sense of it. Initially that we assumed that the...
May 15, 2024
The current Ozempic shortage has been driven by the increase in demand as the drug is being used to treat obese patients for long term weight management, in addition to the original group of type 2 diabetes patients. A study run by the University College London (UCL),...
Apr 18, 2024
The vast majority of discounts available to Pharmacist and Dispensing Doctors are between 0% and 19.9%, with the average at 11%. Most manufacturers do not attempt to compete with parallel imports, as they see it, quite rightly, as competing with themselves. However,...
Feb 27, 2024
In Parliament his month questions were posed to Andrew Stephenson, Secretary of State for Health and Social Care by Peter Grant MP (SNP). He asked ‘What steps the Department is taking to ensure that there is an adequate supply of Oxcarbazepine for patients with...
Feb 8, 2024
WaveData conducted a comparison of the average market prices given to accounts (pharmacies and dispensing doctors) by respiratory product manufacturers. The average discounts given over a 10 year period are very consistent at 9%, which probably reflects the underlying...
